Navigation Links
New oral agents may prevent injury after radiation exposure
Date:7/10/2009

(Boston) Researchers from Boston University School of Medicine (BUSM) and collaborators have discovered and analyzed several new compounds, collectively called the ''EUK-400 series,'' which could someday be used to prevent radiation-induced injuries to kidneys, lungs, skin, intestinal tract and brains of radiological terrorism victims. The findings, which appear in the June issue of the Journal of Biological Inorganic Chemistry, describe new agents which can be given orally in pill form, which would more expedient in an emergency situation.

These agents are novel synthetic "antioxidants" that protect tissues against the kind of damage caused by agents such as "free radicals." Free radicals, and similar toxic byproducts formed in the body, are implicated in many different types of tissue injury, including those caused by radiation exposure. Often, this kind of injury occurs months to years after radiation exposure. The BUSM researchers and their colleagues are developing agents that prevent injury even when given after the radiation exposure.

This paper describes a newer class of compounds, the ''EUK-400 series,'' that are designed to be given as a pill. According to the researchers, experiments described in their paper prove that these agents are orally active. They also show that the new agents have several desirable "antioxidant" activities, and protect cells in a "cell death" model.

These same BUSM researchers and collaborators had previously discovered novel synthetic antioxidants that effectively mitigate radiation injuries, but had to be given by injection. "We have developed some of these agents and have studied them for over 15 years beginning with our work at the local biotechnology company Eukarion," said senior author Susan Doctrow, PhD, a research associate professor of medicine at BUSM's Pulmonary Center. "These injectible antioxidants are very effective, but there has also been a desire to have agents that can be given orally. A pill would be more feasible than an injection to treat large numbers of people in an emergency scenario," she adds.

Future studies will focus on the EUK-400 compounds' effects in various experimental models for radiation injury. Data showing their benefits in models for radiation injury in blood vessel cells have been presented at two major scientific conferences and will be the topic of future publication. More broadly, beyond the potential for treating victims of radiological terrorism, these compounds could also be useful drugs against a variety of diseases where an effective antioxidant has potential benefits, for example, various neurological, pulmonary, cardiovascular, and autoimmune disorders. Previously, Doctrow's lab and others have published studies showing that the injectible versions of these compounds are beneficial in models for several such diseases.


'/>"/>

Contact: Allison Rubin
allison.rubin@gmail.com
617-638-8490
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
2. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
3. ABR-Affinity BioReagents Expands 100% Quality Guarantee
4. Inside job: new radioactive agents for colon cancer work inside cells
5. ABR -- Affinity BioReagents Announces Launch of New Website
6. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
7. Controversial physical agents directive postponed
8. Health Insurance Agents Warn Against Imposing a Health Care Reform Tax in California
9. ABR-Affinity BioReagents Announces Its Continued Support for the Society for Neuroscience Annual Meeting in San Diego, November 3 - 7, 2007
10. Benepath Launches Exclusive Marketing Service for Health Insurance Agents and Agencies
11. National Patient Advocate Foundation (NPAF) Statement Regarding New FDA Label on Erythropoietin Stimulating Agents (ESAs)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... TherapySites, the leading website and ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to extend ... exclusive benefits and promotional offers. , "TCA is extremely excited about this new ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... 2016 , , , WHEN: ... 2016 , , , , LOCATION: , , , Online, ... , , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global ... Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager ... pharmaceutical industry is witnessing an exceptional era. Several new demand spaces, ...
Breaking Medicine Technology: